Abstract:
The present invention is directed toward the isolation, characterization and pharmacological use of the human D4 dopamine receptor. The nucleotide sequence of the gene corresponding to this receptor and alleleic variants thereof are provided by the invention. The invention particularly provides recombinant eukaryotic expression constructs capable of expressing the human D4 dopamine receptor at useful levels in cultures of transformed eukaryotic cells. The invention provides cultures of transformed eukaryotic cells which synthesize such useful amounts of human D4 dopamine receptor protein, and methods for characterizing novel psychotropic compounds using such cultures.

Description:
This invention was made with government support under NIMH grant MH-48991 awarded by the National Institutes of Health, Unites States of America. The government has certain rights in the invention. 
    
    
     This application is a continuation-in-part of U.S. patent application Ser. No. 07/928,611, filed on Aug. 10, 1992, which is a continuation-in-part of U.S. patent application Ser. No. 07/626,618, filed on Dec. 7, 1990, U.S. Pat. No. 5,422,265, both of which are hereby incorporated by reference. 
    
    
     BACKGROUND OF THE INVENTION 
     1. Field of the Invention 
     The invention relates to dopamine receptors from mammalian species and the genes corresponding to such receptors. In particular, it relates to the human dopamine receptor D4. Specifically, the invention relates to the construction of recombinant expression constructs capable of expressing the human D4 dopamine receptor in cultures of transformed eukaryotic cells and the production of human D4 dopamine receptor protein in such cultures. The invention relates to the use of such cultures of transformed eukaryotic cells producing the human D4 dopamine receptor for the characterization of antipsychotic drugs. 2. Description of the Related Art 
     Dopamine is a neurotransmitter that participates in a variety of different functions mediated by the nervous system, including vision, movement, and behavior (see generally Cooper et al., 1978, The Biochemical Basis of Neuropharmacology, 3d ed., Oxford University Press, New York, pp. 161-195). The diverse physiological actions of dopamine are in turn mediated by its interaction with one of the five known types of G protein-coupled receptors (D 1, D2, D3, D4 and DS), which either stimulate or inhibit the enzyme adenylyl cyclase in response to dopamine binding (Kebabian &amp; Calne, 1979, Nature 277: 93-96). Alterations in the number or activity of these receptors may be a contributory factor in human disease such as Parkinson&#39;s disease (a movement disorder) and schizophrenia (a behavioral disorder). 
     A great deal of information has accumulated on the biochemistry of the D1 and D2  dopamine receptors, the archetypal dopamine receptors and the first to be studied, and methods have been developed to solubilize and purify these receptor proteins (see Senogles et al., 1986, Biochemistry 25: 749-753; Sengoles et al., 1988, J. Biol. Chem. 263: 18996-19002; Gingrich et al., 1988, Biochemistry 27: 3907-3912); said methods have been adapted to study the other types of dopamine receptors as well. 
     The D1 dopamine receptor in several tissues appears to be a glycosylated membrane protein of about 72 kD (Amlalky et al., 1987, Mol. Pharmacol. 31: 129-134; Niznik et al., 1988, Biochemistry 27: 7594-7599). The D2 receptor has been suggested to have a higher molecular weight of about 90-150 kD (Amlalky &amp; Caron, 1985, J. Biol. Chem. 260: 1983-1986; Amlaiky &amp; Caron, 1986, J. Neurochem. 47: 196-204; Jarvie et al., 1988, Mol. Pharmacol. 34: 91-97). A recently discovered additional dopamine receptor, termed D3 (Sokoloffet al., 1990, Nature 347: 146-151) has been shown to be expressed via an alternatively spliced mRNA, to produce proteins differing by the presence or absence of a 21 amino acid portion of the third cytoplasmic domain (Fishburn et al., 1993, J. Biol. Chem. 268: 5872-5878). Boundy et al. have used a baculovirus expression system to produce sufficient D3 protein to raise antibodies useful in immunoprecipitation and immunoblot assays of D3 receptor protein (1993, J. Pharmacol. Exper. Therap. 264: 1002-1011). 
     Dopamine receptors are primary targets in the clinical treatment of psychomotor disorders such as Parkinson&#39;s disease and affective disorders such as schizophrenia (Seeman et al., 1987, Neuropsychopharm. 1: 5-15; Seeman, 1987, Synapse 1: 152-333). The different dopamine receptors have been cloned as a result of nucleotide sequence homology between these receptor genes (Bunzow et al., 1988, Nature 336: 783-787; Grandy et al., 1989, Proc. Natl. Acad. Sci. USA 86: 9762-9766; Dal Toso et al., 1989, EMBO J. 8: 4025-4034; Zhou et al., 1990, Nature 346: 76-80; Sunahara et al., 1990, Nature 346: 80-83; Sokoloff et al., 1990, Nature 347: 146-151; Van Tol et al., 1991, Nature 350: 610-614; Van Tol et al., 1992, Nature 358: 149-152; Sunahara et al., 1991, Nature 350: 614-619). 
     The antipsychotic clozapine is useful for socially withdrawn and treatment-resistant schizophrenics (see Kane et al., 1990, Nature 347: 146-151), but unlike other antipsychotic drugs, clozapine does not cause tardive dyskinesia (see Casey, 1989, Psychopharmacology 99:  547-553). Clozapine cannot exert its effects via the D2 or D3 receptors, however, because the dissociation constants of D2 and D3 for clozapine are 3 to 30-fold higher than the therapeutic free concentration of clozapine in plasma water (Ackenheil et al., 1976, Arzneim-Forsch 26: 1156-1158; Sandoz Canada, Inc., 1990, Clozaril: Summary of preclinical and clinical dam). This observation suggested the existence of dopamine receptors more sensitive to the antipsychotic clozapine than D2 or D3. 
     Some of the present inventors have isolated and characterized the gene for the only known clozapine-reponsive human dopamine receptor, D4 (see U.S. patent application Ser. Nos. 07/928,611 and 07/626,618, both incorporated by reference). The human D4 dopamine receptor gene displays a high degree of homology to the human dopamine D2 and D3 receptor genes. The pharmacological profile of the receptor protein encoded by and produced by expression of this gene also resembles the D2 and D3 receptors, but has 10-fold higher affinity for clozapine. 
     Some of the same present inventors have also discovered that the D4 gene is polymorphic in the human population, having at least 7 different alleles that can be detected by restriction fragment length polymorphism analysis (see, Botstein et al., 1980, Am. J. Hum. Genet. 32: 314-331). This is the first human receptor gene in the catecholamine receptor family which displays such polymorphic variations in the coding region. The observed polymorphism in dopamine D4 receptor genes may underlie individual differences in susceptibility to neuropsychiatric disorders such as schizophrenia and manic depression, as well as responsiveness to antipsychotic medication. 
     Expression of these varying alleles of this clozapine-sensitive dopamine receptor protein receptor provides a useful method for screening putative psychotopic drugs in vitro to enable the discovery of new types of drugs for treatment of human diseases such as schizophrenia, which may share clozapine&#39;s useful and advantageous properties of not inducing tardive dyskinesia and other motor side effects. 
    
    
     DESCRIPTION OF THE DRAWINGS 
     FIGS. 1A to 1E illustrates the nucleotide [SEQ ID No.: 1] and amino acid [SEQ ID No.:2] sequences of human D4 dopamine receptor allele D4.2. 
     FIGS. 2A to 2E illustrates the nucleotide [SEQ ID No.: 3] and amino acid [SEQ ID No.: 4] sequences of human D4 dopamine receptor allele D4.4. 
     FIGS. 3A to 3F illustrates the nucleotide [SEQ ID No.: 5] and amino acid [SEQ ID No.: 6] sequences of human D4 dopamine receptor allele D4.7. 
     FIG. 4 schematically illustrates the construction of the vaccinia virus-based recombinant expression construct hD4.2. 
     FIG. 5 shows the binding of [ 3  H]spiperone to membranes of cells infected with the vaccinia virus-based recombinant expression construct hD4.2. 
     FIG. 6 demonstrates the pharmacological specificity of [ 3  H]spiperone binding to membranes of cells infected with the vaccinia virus-based recombinant expression construct hD4.2. 
     FIG. 7 illustrates Scatchard analysis of pharmacological data on specificity of [ 3  H]spiperone binding to membranes of cells infected with the vaccinia virus-based recombinant expression construct hD4.2. 
    
    
     SUMMARY OF THE INVENTION 
     The present invention is directed toward the isolation, characterization and pharmacological use of the human D4 dopamine receptor, the gene corresponding to this receptor, recombinant eukaryotic expression constructs capable of expressing the human D4 dopamine receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize the human D4 dopamine receptor. 
     It is an object of the invention to provide a nucleotide sequence encoding a mammalian dopamine receptor. Further, it is an object of the invention to provide a nucleotide sequence that encodes a mammalian dopamine receptor with novel and distinct pharmacological properties. It is specifically an object of the invention to provide a nucleotide sequence encoding a mammalian dopamine receptor having the particular drug dissociation properties of the human dopamine receptor D4. In particular, the mammalian dopamine receptor encoded by the nucleotide sequence of the present invention has a high affinity for the drug clozapine. The human D4 dopamine receptor embodied in the present invention shows a dissociation constant (termed K i ) of 1-40 nanomolar (nM), preferably 1-20 nM, most preferably 11 nM clozapine, as detected by the [ 3  H]spiperone binding assay disclosed herein. The human D4 dopamine receptor embodied in the present invention displays the following pharmacological profile of inhibition of [ 3  H]spiperone binding in the [ 3  H]spiperone binding assay: spiperone&gt;eticlopride&gt;clozapine&gt;(+)-butaclamol&gt;raclopride&gt;SCH23390. In a preferred embodiment of the invention, the nucleotide sequence encoding a dopamine receptor encodes the human dopamine receptor D4. 
     The present invention provides a nucleic acid having a nucleotide sequence encoding a mammalian dopamine receptor that is the human D4 receptor. In preferred embodiments, this nucleotide sequence comprises eDNA sequences and genomic DNA sequences of naturally occurring alleles of the human D4 dopamine receptor, most preferably the eDNA sequences of the D4.2, D4.4 and D4.7 alleles (SEQ ID Nos.: 1, 3 &amp; 5, respectively). The invention includes nucleic acid having a nucleotide sequence of allelic variations of this nucleotide sequence and the corresponding D4 receptor molecule, either naturally occurring or the product of in vitro chemical or genetic modification, having essentially the same nucleotide sequence as the nucleotide sequence of the human D4 receptor disclosed herein, wherein the resulting human D4  receptor molecule has substantially the same drug dissociation properties of the human D4 receptor molecule corresponding to the nucleotide sequence described herein. Allelic variations of this nucleotide sequence and the corresponding D4 receptor molecule, either naturally occurring or the product of in vitro chemical or genetic modification, having essentially the same nucleotide sequence as the nucleotide sequence of the human D4 receptor disclosed herein, wherein the resulting human D4 receptor molecule has substantially the same drug dissociation properties of the human D4 receptor molecule corresponding to the nucleotide sequence described herein are additional preferred embodiments of the invention. Specific preferred embodiments include alleles D4.2, D4.4 and D4.7 of the human D4 dopamine receptor gene, as defined herein and in co-pending U.S. patent application Ser. No. 07/928,611. 
     The invention also includes a predicted amino acid sequence for the human D4 dopamine receptor deduced from the nucleotide sequence comprising the complete coding sequence of the D4 dopamine receptor gene [SEQ ID Nos: 2,4 &amp; 6]. Specific preferred embodiments comprise the amino acid sequence of the naturally-occurring alleles of the human D4 dopamine receptor gene. Allelic variations of this amino acid sequence and the corresponding D4 receptor molecule, either naturally occurring or the product of in vitro chemical or genetic modification, having essentially the same amino acid sequence as the human D4 receptor disclosed herein, wherein the human D4 receptor molecule has substantially the same drug dissociation properties of the human D4 receptor molecule corresponding to the amino acid sequence described herein are additional preferred embodiments of the invention. Specific preferred embodiments include the alleles D4.2, D4.4 and D4.7. 
     In addition, this invention includes recombinant DNA constructs comprising the human D4 dopamine receptor and sequences that mediate the replication and selected growth of microorganisms that carry this construct. In preferred embodiments, such DNA constructs comprise the recombinant vector pZVneo. 
     The present invention provides recombinant expression constructs comprising the nucleotide sequence of the human D4 dopamine receptor and sequences sufficient to direct the synthesis of the human D4 dopamine receptor protein in cultures of transformed eukaryotic cells. In preferred embodiments, the recombinant expression construct is comprised of plasmid sequences derived from a mammalian virus, most preferably vaccinia virus, and D4 dopamine receptor sequences corresponding to eDNA or genomic sequences for alleles D4.2, D4.4 and D4.7, as defined herein, as well as a hybrid human D4 dopamine gene, for example, as disclosed in co-pending U.S. patent application Serial No. 07/626,618, U.S. Pat. No. 5,422,265. Recombinant expression constructs of the invention also encompass embodiments comprising allelic variations of the human D4 dopamine receptor genomic DNA sequences and eDNA-derived sequences. This invention includes recombinant expression constructs comprising essentially the nucleotide sequences of genomic and eDNA clones of the human D4 dopamine receptor and allelic variations thereof in embodiments that provide for the expression of human D4 dopamine receptor protein in cultures of transformed eukaryotic cells. It is a particular advantage of the present invention that the vaccinia virus-based recombinant expression constructs of the invention have a wide host range and are capable of infecting most mammalin cell cultures known in the art. 
     It is also an object of this invention to provide cultures of transformed eukayotic cells that have been transformed with such recombinant expression constructs and that synthesize human D4 dopamine receptor protein. In a preferred embodiment, the invention provides monkey COS cells that synthesize human D4 dopamine receptor protein. In a particularly preferred embodiment, such cultures are produced by infection of said cells of said cultures with a recombinant human D4-vaccinia virus based construct, most preferably the construct hD4 described hereinbelow. 
     The present invention also includes membrane preparations comprising human D4 receptor protein, derived from cultures of mammalian cells transformed with the recombinant expression constructs of the invention. In a preferred embodiment, cell membranes containing human D4 dopamine receptor protein are isolated from cultures of Ltk cells infected with a vaccinia virus-based recombinant expression construct that directs the synthesis of human D4 dopamine receptor. It is a particular advantage of the present invention that the cultures of cells transformed with the recombinant expression constructs of the invention are capable of producing the D4 receptor protein on the surface of such transformed cells in amount corresponding to about 1 pmol/mg membrane protein. 
     It also an object of this invention to provide the human D4 dopamine receptor for use in the in vitro screening of novel antipsychotic compounds. In a preferred embodiment, membrane preparations containing the human D4 dopamine receptor, derived from cultures of eukaryotic cells transformed with the recombinant expression constructs of the invention, are used to determine the drug dissociation properties of antipsychotic compounds in vitro. These properties are then used to characterize novel antipsychotic compounds by comparison to the binding properties of known antipsychotic compounds. 
     The present invention will also be useful for the detection of dopamine and dopamine analogues, known or unknown, either naturally occurring or as the embodiments of antipsychotic or other drugs. 
     It is an object of the present invention to provide a method for the quantitative detection of dopamine and dopamine analogues, either naturally occurring or as the embodiments of antipsychotic or other drugs. It is an additional object of the invention to provide a method to detect dopamine or dopamine analogues in blood, saliva, semen, cerebrospinal fluid, plasma, lymph, or any other bodily fluid. 
     Further uses of the invention include production of sufficient human dopamine D4 receptor protein to provide an effective antigenie inoculum for raising anti-D4 antisera in animals and in producing animal immune cells specific for human D4 epitopes for use in producing hybridomas producing anti-D4 monoclonal antibodies. 
     DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS 
     The term &#34;D4 dopamine receptor&#34; as used herein refers to proteins substantially homologous to, and having substantially the same biological activity as, the protein coded for by the nucleotide sequences depicted in FIGS. 1A to 1E, 2A to 2E and 3A to 3F. (i.e., proteins which display high affinity binding to clozapine) [SEQ ID Nos: 1,3,&amp; 5]. This definition is intended to encompass natural allelic variations in the D4 dopamine receptor sequence, specifically including the alleles D4.2, D4.4 and D4.7, as defined herein, and all references to the D4 dopamine receptor, and nucleotide and amino acid sequences thereof are intended to encompass such allelic variations, both naturally-occurring and man-made. Cloned genes of the present invention may code for D4 dopamine receptors of any species of origin, including, mouse, rat, rabbit, cat, and human, but preferably code for receptors of mammalian, most preferably human, origin. 
     The production of proteins such as the D4 dopamine receptor from cloned genes by genetic engineering is well known (see, e.g., U.S. Pat. No. 4,761,371 to Bell et al. at Col. 6 line 3 to Col. 9 line 65; the disclosure of all U.S. patent references cited herein is to be incorporated herein by reference). The discussion which follows is accordingly intended as an overview of this field, and is not intended to reflect the full state of the art. 
     DNA which encodes the D4 dopamine receptor may be obtained, in view of the instant disclosure, by chemical synthesis, by screening reverse transcripts of mRNA from appropriate tissues, cells or cell line cultures, by screening genomic libraries from appropriate cells, or by combinations of these procedures. Screening of mRNA or genomic DNA may be carded out with oligonucleotide probes generated from the D4 dopamine receptor gene sequence information provided herein. Probes may be labeled with a detectable group such as a fluorescent group, a radioactive atom or a chemiluminescent group in accordance with known procedures and used in conventional hybridization assays, as described in greater detail in the Examples below. In the alternative, D4 dopamine receptor gene sequences may be obtained by use of the polymerase chain reaction (PCR) procedure, with the PCR oligonucleotide primers being produced from the D4-dopamine receptor gene sequence provided herein (see U.S. Pat. Nos. 4,683,195 to Mullis et al. and 4,683,202 to Mullis). 
     The D4 dopamine receptor may be synthesized in host cells transformed with constructs containing DNA encoding the D4 dopamine receptor. For the purposes of this invention, the term &#34;transformed&#34; is intended to encompass any method for introducing recombinant expression constructs of the invention into mammalian cells, including but not limited to transfection, electroporation, microinjection, osmotic shock, receptor endocytosis and most preferably, infection via viral-mediated mechanisms. The constructs of the invention are replicable and are used herein either to amplify DNA encoding the D4 dopamine receptor and/or to express DNA which encodes the D4 dopamine receptor. An expression construct is a replicahie DNA construct in which a DNA sequence encoding the D4 receptor is operably linked to suitable control sequences capable of effecting the expression of the D4 receptor in a suitable host. The need for such control sequences will vary depending upon the host selected and the transfection method chosen. Generally, control sequences include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and sequences which control the termination of transcription and translation. When used for DNA amplification such constructs do not require expression control domains. All that is needed is the ability to replicate in a host, usually conferred by an origin of replication, and a selective marker gene to facilitate recognition of transformants. 
     Constructs useful for practicing the present invention include plasmids, viruses (including phage), retroviruses, and integratable DNA fragments (i.e., fragments integratable into the host genome by homologous recombination). The construct may replicate and function independently of the host genome, or may, in some instances, integrate into the host genome itself. Suitable constructs will contain replicon and control sequences which are derived from species compatible with the intended expression host. Preferred recombinant expression constructs comprise a nucleic acid consisting essentially of genomic or cDNA sequences of an allele of human D4, operatively linked to a nucleic acid comprising sequences derived from vaccinia virus. 
     DNA regions are operably linked when they are functionally related to each other. For example: a promoter is operably linked to a coding sequence if it controls the transcription of the sequence; a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation. Generally, operably linked means contiguous and, in the case of leaders sequences, contiguous and in the same translational reading frame. 
     Transformed host cells are cells which have been transformed, transfected or infected with the D4 receptor-containing constructs assembled using recombinant DNA techniques. Transformed host cells ordinarily express the D4 receptor, but host cells transformed for purposes of cloning or amplifying the D4 receptor DNA need not express the D4 receptor. When expressed, the D4 receptor will typically be located in the host cell membrane. 
     Cultures of cells derived from multicellular organisms are a desirable host for recombinant D4 dopamine receptor synthesis. In principal, any higher eukaryotic cell culture can be used, whether from vertebrate or invertebrate culture. However, mammalian cells are preferred, as illustrated in the Examples. Propagation of such cells in cell culture has become a routine procedure (see Tissue Culture, Academic Press: New York (Kruse &amp; Patterson, eds.) 1973). Examples of useful host cell lines are VERO cells, HeLa cells, Chinese hamster ovary (CHO) cells, and WI138, BHK, COS-7, CV, and MDCK cell lines. Preferred cells are mouse Ltk -  cells. 
     Expression constructs for such cells ordinarily include (if necessary) an origin of replication, a promoter located upstream from the gene to be expressed, along with a ribosome binding site, RNA splice site (if intron-containing genomic DNA is used), a polyadenylation site, and a transcriptional termination sequence. In preferred embodiments, these functionalities are provided by a nucleic acid derived from vaccinia virus DNA. Alterative embodiments comprise transcriptional and translational control sequences provided by other viral sources, such as baculovirus, polyomavirus, adenovirus, and simian virus 40 (SV40; see, e.g., U.S. Pat. No. 4,599,308). In additional alternatives, the human genomic D4 receptor promoter, control and/or signal sequences, may also be used, provided such control sequences are compatible with the host cell chosen. 
     D4 dopamine receptors made from cloned genes in accordance with the present invention may be used for screening compounds for D4 dopamine receptor activity, or for determining the amount of a dopaminergic drug in a solution (e.g., blood plasma or serum). For example, host cells may be transformed with a construct of the present invention, D4 dopamine receptors expressed in that host, the cells lysed, and the membranes from those cells used to screen compounds for D4 dopamine receptor binding activity. Competitive binding assays in which such procedures may be carried out are well known, as illustrated by the Examples below. By selection of host cells which do not ordinarily express a dopamine receptor, pure preparations of membranes containing D4 receptors can be obtained. Further, D4 dopamine receptor agonist and antagonists can be identified by transforming host cells with constructs of the present invention. Membranes obtained from such cells can be used in binding studies wherein the drug dissociation constants are measured. Such cells must contain D4 protein in the plasma and other cell membranes. Procedures for carrying out assays such as these are also described in greater detail in the Examples which follow. 
     Cloned genes and constructs of the present invention are useful to transform cells which do not ordinarily express the D4 dopamine receptor to thereafter express this receptor. Such cells are useful as intermediates for making cell membrane preparations for receptor binding assays, which are in turn useful for drug screening. 
     The Examples which follow are illustrative of specific embodiments of the invention, and various uses thereof. They are set forth for explanatory purposes only, and are not to be taken as limiting the invention. 
     EXAMPLE 1 
     Isolation and Characterization of Human D4 Dopamine Receptor Alelles 
     The isolation, nucleotide sequencing, analytical expression using SV40-based recombinant expression constructs, and biochemical characterization of the dopamine receptor proteins produced therefrom in mammalian cell culture transformed with such recombinant expression constructs, is described more fully in U.S. patent applications, Ser. Nos. 07/626,618, U.S. Pat. No. 5,422,265, and 07/928,611, hereby incorporated by reference. The nucleotide and amino acid sequences of human D4 receptor alleles D4.2 [SEQ ID Nos.: 1 &amp; 2], D4.4 [SEQ ID Nos: 3 &amp; 4]and D4.7 [SEQ ID Nos.: 5 &amp; 6] are presented in FIGS. 1A to 1E, 2A to 2E and 3A to 3F, respectively. 
     EXAMPLE 2 
     Construction of Vaccinia Virus-Based Recombinant Expression Constructs for Expressing Human D4 Receptor Protein in Mammalian Cells 
     In order to provide transformed culture of mammalian cells expressing the human D4 receptor protein, vaccinia virus-based recombinant expression constructs were produced as follows using methods well known in the art (see Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press: New York). A schematic drawing of the cloning strategy is shown in FIG. 4. 
     A full-length human D4 dopamine receptor eDNA clone encoding the D4.4 allde (see van Tol et al., 1992, Nature 358: 149-152 and U.S. patent application Ser. No. 07/928,611, filed Aug. 10, 1992) was digested with BamHI to liberate the eDNA sequences. The eDNA sequences were then ligated into the vaccinia virus recombination vector pZVneo using methods known in the an (Sambrook et al., ibid.). Recombinant clones containing the D4 sequences oriented properly for expression were determined by restriction enzyme mapping. Similar recombinant constructs are produced from clones encoding the D4.2 and D4.7 alleles. 
     One such construct, pZVneo.hD4.4, was then transfected into a culture of human HeLa cells previously infected with wild-type vaccinia virus. HeLa cells were grown in minimal esential media (MEM; GIBCO, Long Island, N.Y.) supplemented with 10% heat-inactivated fetal calf serum (FCS; GIBCO) to approximately 50% confluency in 100cm culture dishes (Falcon, Lincoln Park, N.J.). The cells were then trypsinized with a solution of 0.05 % trypsin in versine (phopshate buffered saline+1 mM ethylenediamine tetraacetic acid (EDTA)+0.0075 % phenol red) by incubating for about 1 min at 37° C. To each plate was added 1 mL of DMEM, and a 100μL aliquot was then mixed with trypan blue (GIBCO) and the number of viable cells/mL determined using a hemocytometer and phase-contrast microscopy. HeLa cells were then plated at a density of 5×10 5  cells/4 cm dish and incubated at 37° C. The cells were allowed to attach to the dish, and then were rinsed with PBS-MB (phosphate buffered saline+1 mM MgCl 2  +0.1% bovine serum albumin at 4° C. Wild-type vaccinia virus was then added to each 4 cm dish at a concentration of 0.5-1 plaque-forming units (pfu)/cell and incubated 0.5-1h at room temperature. 
     After incubation, the PBS-MB was removed and each dish washed three times with DMEM (without serum supplement). 1 mL of DMEM was then added per dish and 100μL of a mixture containing 5μg pZVneo-hD4 and lipofectin (GIBCO) was added dropwise as the plates were gently rocked to mix. The plates were then incubated for 3h at 37° C. The transfection mixture was then removed and the cells re-fed with DMEM/10% FCS suplemented with 25μg/mL gentamycin (GIBCO) and incubated at 37° C. overnight. 
     The next day, the cells were harvested and virus liberated using a freeze-thaw regimen with sonication. The cells were harvested using a rubber policeman and transferred to a 50 mL centrifuge tube (Falcon, Cat.//2098). Cells were pelleted by low speed centrifugation (i.e., at 1000-1500 rpm for 5 min in a Sorvall Model RT6000B tabletop centrifuge). The pelleted cells were washed with PBS-M (phosphate buffered saline+1 mM MgCl 2 ) and repelleted. The cells were then resuspended in 1.0 mL PBS-M and subjected to alternative cycles of rapid freezing and thawing (preferably by immersion in dry ice/ethanol to freeze and a water bath at 37°-50° C. to thaw) for a total of three cycles. This crude virus suspension can be then frozen at -70° C. until further use, and was used to prepare plaque-purified D4-recombinant vaccinia virus-based recombinant expression constructs as described in Example 3 below. 
     EXAMPLE 3 
     Plaque Purification of Vaccinia Virus-Based Recombinant Expression Constructs 
     Recombinant vaccinia virus containing hD4 sequences were plaque purified by infection of BSC-40 cells with the crude virus suspension described in Example 2 above. Such crude suspensions are assumed to have a titre of 5.0×10 7  pfu/mL. Several 100 mm plates of BSC-40 cells were prepared at the same time prior to infection so that at least one of the plates could be sacrificed to determine the number of cells/plate. Just prior to infection, media was removed and each plate rinsed with PBS-M. Virus was added at the desired multiplicity of infection (0.5-1 pfu/cell) in an amount of PBS-M just sufficient to cover the surface of the culture dish. The virus aliquot was thawed just prior to infection and added to PBS-M in a polypropylene tube. Just prior to addition to the culture dishes, the virus suspension in PBS-M was either vortexed to sonicated (twice for 10 min) to break up virus aggregates. The virus suspension was then added to each culture dish and the dish gently rocked to ensure even distribution of the virus innoculum. The innoculated cells were kept at room temperature for 0.5-1h with gentle rocking every  5-10 min. Thereafter, the innoculum was removed and the cells re-fed with culture media (MEM/10% FCS) and incubated at 37° C. under the usual culture conditions for 16-48h. 
     For plaque purification assays, a series of plates corresponding to 1000, 100 and 10 plaques were prepared as described above on the assumption that the crude virus suspension contained 107 pfu/mL. Plaque lifts were performed 48h after infection of BSC-40 cells as follows. Three hours before lifting plaques onto filters, 400μL of a 1% solution of neutral red were added to each 100 mM dish and incubated at 37° C. until plaques became visible. For each dish, media was removed and a nylon or nitrocellulose filter [Nytran,(HA85 nitrocellulose, 0.45μm) Shleicher and Schuell, Keene, NH] was carefully placed on the cell monolayer using gloved hands. A tissue (Kimwipe, Kimberly-Clarke, Roswell, Calif.) wetted with PBS-M was used to gently press the filter against the monolayer, taking care not to smear the plaques by sliding over the monolayer. The filter was then separated from the monolayer using a forceps and laid plaque-side up on a piece of Whatman 3MM paper (Whatman, Gladstone, UK) wetted with PBS-MB in a 100 mM petri dish. 
     Next, a nitrocellulose filter (Shleicher &amp; Schuell HA85) was carefully laid atop the first filter using gloved hands, and a Kimwipe wetted with PBS-MB used to carefully press the two filters together. The two filters were oriented to each other by asymetrically marking the filters using a paper punch sterilized with ethanol. The filters were separated using forceps and the second (nitrocellulose) filter placed on a piece of 3MM paper wetted with PBS-M in a 100 mm petri dish and stored at -70° C. until further use. 
     The first filter was used for identifying virus plaques produced by hD4-containing recombinant virus by nucleic acid hybridization using methods well known in the art (see Sambrook et al., ibid. ). First, each filter was floated on a volume of denaturing solution (0.5M NaOH/1.5M NaCl) for 10 min. The filter was then floated twice for 2 min on a volume of neutralization solution (0.5M Tris-HCl, pH 7.5/3.0M NaCl). The filters were then washed once in 2X standard saline citrate (SSC; 1X SSC=0.015M sodium citrate, pH 7.0/0.15M NaCl) and baked for 1-2h at 80° C. (or 20-30 min at 80° C. in vacuo). Filters thus prepared be stored at room temperature until use. 
     For hybridization assays, the filters were prepared as follows. Filters were placed in sufficient volume of proteinase K treatment buffer [50μg/mL freshly added proteinase K in 100 mM Tris-HCl (pH 8.0)/150 mM NaCl/10 mM EDTA/0.2% sodium dodecyl sulfate (SDS)] to completely cover them. The filters were then incubated at 50-55° C. for 30 min. The filters were then removed from this solution and placed in a sealable plastic bag with an excess of prehybridization solution [50% formamide/0.1M NaCl/10% dextran/1% SDS/25μg/mL denatured salmon sperm DNA] and incubated at 37° C. for 2-4h. The filters were then hybridized overnight in the same buffer containing an amount of radioactively-labeled (usually [32P]-dCTP-labeled) nucleic acid hybridization probe specific for human D4 dopamine receptor sequences (made using means well known in the art; see Sambrook et al., ibid.). After hybridization, probe solution was removed and the filters washed sequentially as follows: first, for 10 min at room temperature in 2X SSC; next, for 30-60 min at 65° C. in 2X SSC/1% SDS; and lastly for 10-30 min at room temperature in 0.1X SSC. The filters were wrapped in plastic film and placed under X-ray film (Kodak XAR-5, Rochester, NY) at -70° C. for a time appropriate for visuallizing D4-positive plaques. 
     Plaques were isolated for further plaque purification as follows. After visuallizing the D4-positive plaques by developing the X-ray film described above, the second set of nitrocellulose filters were oriented to the image from their cognate first filter using the previous asymetric paper punch code. An area of nitrocellulose corresponding to each of a multiplicity of D4-positive plaques was removed from the second nitrocellulose filter (preferably using an ethanol-sterilized paper punch). Each such nitrocellulose dot was placed in a plastic tube (Falcon Cat. #2063) to which was added 200μL PBS-MB. The tubes were vortexed and/or sonicated for 1 min and subjected to 3 rounds of freeze/thaw. Virus was then grown from each isolated plaque by infection of BSC-40 cells as described above using 100μL of each plaque suspension; the remaining 100μL was stored at -70° C. Further rounds of plaque purification were performed essentially as described herein until every plaque was D4-positive in the hybridization assay. Plaque-pure suspensions were then used to prepare virus stocks of D4 recombinant phage as described in Example 4 below. 
     EXAMPLE 4 
     Production of Purified Stocks of Recombinant Human D4 Dopamine Receptor-Containing Vaccinia Virus 
     As a final step in the plaque purification protocol described in Example 3 above, assays were also performed using an agar overlay technique. In this assay, following plaque-purified virus adsorption to cells on 100 mm plates, 10 mL of a mixture of 0.75% agar (SeaPlaque, FMC Corp. Rockland, Me.) in MEM/10%FCS was added to each plate and allowed to harden at room temperature for 15 min. Infected cells were then incubated under the usual conditions at 37° C. for 48h. The infected dishes were then treated by the addition of 5mL of a 1% solution of agar in water containing 200μL of a solution of 1% neutral red. The agar was again allowed to cool for 15 min at room temperature and the cells incubated at 37° C. for 2-3h to allow the dye to stain the cells. (Plaques appear as clear spots in red-stained cell monolayer). Plaques were then isolated by impaling an agar plug over the plaque with a Pasteur pipette and aspirating the plug into the pipette tip. Each agar plug was then expelled from the pipette into 200μL PBS-M in a 4 mL plastic tube (Falcon Cat #2063), and subjected to freeze/thaw disruption to liberate recombinant virus. 
     Large-scale preparations of plaque-purified D4-recombinant virus prepared as described herein, with the exception that plaque-purified infections were performed at a multiplicity of infection of 0.005 pfu/cell. BSC-40 cells were grown to confluency on 5 150mm culture dishes. The number of cells on one plate were counted to provide an estimate of the number of cells on the other 4 plates. Plaque-purified, titred virus stock was thawed, vortexed and/or sonicated briefly (10 sec) and placed on ice. Sufficient virus was added to 12 mL cold PBS-MB to correspond to 0.005 pfu/cell and 3mL/plate. Cells prepared for infection by removing media and washing once with warm PBS-MB. This solution was removed and 3mL of cold PBS-MB containing virus was added per plate. Virus was allowed to adsorb for 30 min at room temperature with gentle rocking every 5-10 min. The virus innoculum was then removed and each of the dishes re-fed with 20mL MEM +10% heat-inactivated FCS. Cells were incubated for 48-72h at 37° C. 
     Virus was isolated by scraping the cells (still in culture media) using a rubber policeman. The cell suspension was then transferred to a 50 mL conical plastic centrifuge tube (Falcon Cat #2098). The cells were pelleted by low speed centrifugation as described above in Example 2 and resuspended in 10 mL PBS-MB. The cells were re-pelleted and then resuspended in 5 mL of a cold solution of 10 mM Tris (pH 9.0) and placed on ice. All steps hereinafter in this preparation were performed on ice. The cell suspension was then placed in a chilled Dounce homogenizer (Kontes Pestel A) and disrupted by 25 strokes. The disrupted cell suspension was transferred to a 15 ml screw-cap tube (Sarstedt, Newton, N.C.) and cell debris pelleted at 4° C. for 5 min at 2000 rpm in a Sorvall RT6000B centrifuge. The supernatant was transferred to a Beckman SW28 ultracentrifuge tube, and the pellet resuspended in 5 mL ice-cold 10 mM Tris (pH 9.0) and repelleted. The supernatant from this second low-speed centrifugation was pooled with the first supernatant. 
     The pooled supernatant was underlayed with 16 mL of a 36 % sucrose solution prepared in 10 mM Tris (pH 9.0). The supernatant was then ultracentrifuged at 18,000 rpm in a Beckman SW28 rotor for 80 min at 4° C. to pellet recombinant virus. After ultracentrifugation, the supernatant was removed from the visible virus pellet by aspiration, and the pellet resuspended in 1.0-1.5 mL 10 mm Tris (pH 9.0). This suspension was dounced about 7 times on ice to provide a suspension having a milky, even consistency. The recombinant virus suspension was then transferred in 20-40μL aliquots to 2 mL plastic screw-capped FALCON tubes, titred and stored at -70° C. Typical virus stocks prepared in this way were found to have viral titres of about 10 10  pfu/mL. 
     EXAMPLE 5 
     Production of Human D4 Dopamine Receptor Protein in Mammalian Cell Cultures 
     Human D4 dopamine receptor protein was produced in mammalian cell cultures using the recombinant expression construct described in Example 2. Briefly, a culture of 10 6  mouse Ltk -  cells (that do not produce an endogenous dopamine receptor) were infected with plaquepurified human D4 receptor-vaccinia virus recombinant expression construct as described above at a multiplicity of infection of 5 pfu/cell. Cells were harvested 16h after infection and a crude plasma membrane preparation prepared essentially as described in Zhou et al. [1990, Nature 347: 76-79] and co-pending U.S. patent application Ser. No. 07/928,611. Briefly, cells were harvested and homogenized using a teflon pestle in 50 mM Tris-HCl (pH 7.4 at 4° C.) buffer containing 5 mM EDTA, 1.5 mM CaCl 2 , 5 mM MgCl 2 , 5 mM KCl and 120 mM NaCl. Homogenates were pelleted by centrifugation at 800 g for 10 min, re-homogenized and re-pelleted, and then the supernatant fluid ultracentrifiged at 100,000  g for 30-60 min at 4° C. The resulting pellets were resuspended in buffer at a concentration of 150-250 μg/ml. Membrane preparations were stored at -80° C. until use in ligand binding experiments, as described below. 
     EXAMPLE 6 
     Analysis of Dopamine and Dopamine-Antagonist Binding of D4 Dopamine Receptor 
     Ligand binding experiments were performed essentially as described in Bunzow et al. [1988, Nature 336: 783-787] and in co-pending U.S. patent application Ser. No. 07/928,611. In binding experiments, increasing amounts of membrane protein was incubated with [ 3  H]spiperone (70.3 Ci/mmol; 10-3000 pM final concentration) for 120 min at 22° C. in a total volume of 1 ml. The results of these experiments are shown in FIGS. 5 and 6. The results shown are representative of two independent experiments each conducted in duplicate. The results show specific binding that increases to saturation with increased membrane protein concentration. These results confirm that the infected cell cultures produce human D4 protein. 
     For Scatchard analysis experiments, 0.25 ml aliquots of crude plasma membrane homogenate from hD4 recombinant vaccinia virus-infected cell cultures was incubated in duplicate with increasing concentrations of [ 3  H]spiperone (70.3 Ci/mmol; 10-3000 pM final concentration) under conditions described above. The estimated value for B max  was derived from these data were obtained using the LIGAND computer program. A representative experiment is illustrated in FIG. 6, showing saturable spiperone binding with a K d  =68 pM (in good agreement with previously-obtained values of about 70 pM; Van Tol et al., 1991, Nature 350: 610-614 and co-pending U.S. patent application Ser. No. 07/928,611 ). Scatchard analysis of these data is shown in FIG. 7. The results of these experiments show a nearly 10-fold increase in B max  (approximately 935 fmol/mg protein) over the values obtained using other recombinant expression constructs for human D4 (see co-pending U.S. patent applications Ser. Nos. 07/626,618, U.S. Pat. No. 5,422,265, and 07/928,611 ). These results demonstrate that the instant invention provides a means for producing significantly more D4 receptor protein in cultures of cells trasnformed with the vaccinia virus-based recombinant expression constructs described herein. These results make the instant invention useful in methods for screening novel psychotropic and anti-psychotic drugs for treatment of human diseases related to dopamine and dopamine receptor binding in vivo. 
     It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit and scope of the invention as set forth in the appended claims. 
     
         __________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 6(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1370 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(ix) FEATURE: (A) NAME/KEY: 5&#39;UTR(B) LOCATION: 1..103(ix) FEATURE:(A) NAME/KEY: 3&#39;UTR(B) LOCATION: 1268..1370(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 104..1267(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:CGGGGGCGGGACCAGGGTCCGGCCGGGGCGTGCCCCCGGGGAGG GACTCCCCGGCTTGCC60CCCCGGCGTTGTCCGCGGTGCTCAGCGCCCGCCCGGGCGCGCCATGGGGAACCGC115MetGlyAsnArg 1AGCACCGCGGACGCGGACGGGCTGCTGGCTGGGCGCGGGCGGGCCGCG163SerThrAlaAspAlaAspGlyLeuLeuAlaGlyArgGlyArgAlaAla510 1520GGGGCATCTGCGGGGGCATCTGCGGGGCTGGCTGGGCAGGGCGCGGCG211GlyAlaSerAlaGlyAlaSerAlaGlyLeuAlaGlyGlnGlyAlaAla25 3035GCGCTGGTGGGGGGCGTGCTGCTCATCGGCGCGGTGCTCGCGGGGAAC259AlaLeuValGlyGlyValLeuLeuIleGlyAlaValLeuAlaGlyAsn40 4550TCGCTCGTGTGCGTGAGCGTGGCCACCGAGCGCGCCCTGCAGACGCCC307SerLeuValCysValSerValAlaThrGluArgAlaLeuGlnThrPro55 6065ACCAACTCCTTCATCGTGAGCCTGGCGGCCGCCGACCTCCTCCTCGCT355ThrAsnSerPheIleValSerLeuAlaAlaAlaAspLeuLeuLeuAla7075 80CTCCTGGTGCTGCCGCTCTTCGTCTACTCCGAGGTCCAGGGTGGCGCG403LeuLeuValLeuProLeuPheValTyrSerGluValGlnGlyGlyAla8590 95100TGGCTGCTGAGCCCCCGCCTGTGCGACGCCCTCATGGCCATGGACGTC451TrpLeuLeuSerProArgLeuCysAspAlaLeuMetAlaMetAspVal105 110115ATGCTGTGCACCGCCTCCATCTTCAACCTGTGCGCCATCAGCGTGGAC499MetLeuCysThrAlaSerIlePheAsnLeuCysAlaIleSerValAsp120 125130AGGTTCGTGGCCGTGGCCGTGCCGCTGCGCTACAACCGGCAGGGTGGG547ArgPheValAlaValAlaValProLeuArgTyrAsnArgGlnGlyGly135 140145AGCCGCCGGCAGCTGCTGCTCATCGGCGCCACGTGGCTGCTGTCCGCG595SerArgArgGlnLeuLeuLeuIleGlyAlaThrTrpLeuLeuSerAla150155 160GCGGTGGCGGCGCCCGTACTGTGCGGCCTCAACGACGTGCGCGGCCGC643AlaValAlaAlaProValLeuCysGlyLeuAsnAspValArgGlyArg165170 175180GACCCCGCCGTGTGCCGCCTGGAGGACCGCGACTACGTGGTCTACTCG691AspProAlaValCysArgLeuGluAspArgAspTyrValValTyrSer185 190195TCCGTGTGCTCCTTCTTCCTACCCTGCCCGCTCATGCTGCTGCTGTAC739SerValCysSerPhePheLeuProCysProLeuMetLeuLeuLeuTyr200 205210TGGGCCACGTTCCGCGGCCTGCAGCGCTGGGAGGTGGCACGTCGCGCC787TrpAlaThrPheArgGlyLeuGlnArgTrpGluValAlaArgArgAla215 220225AAGCTGCACGGCCGCGCGCCCCGCCGACCCAGCGGCCCTGGCCCGCCT835LysLeuHisGlyArgAlaProArgArgProSerGlyProGlyProPro230235 240TCCCCCACGCCACCCGCGCCCCGCCTCCCCCAGGACCCCTGCGGCCCC883SerProThrProProAlaProArgLeuProGlnAspProCysGlyPro245250 255260GACTGTGCGCCCCCCGCGCCCGGCCTCCCCCCGGACCCCTGCGGCTCC931AspCysAlaProProAlaProGlyLeuProProAspProCysGlySer265 270275AACTGTGCTCCCCCCGACGCCGTCAGAGCCGCCGCGCTCCCACCCCAG979AsnCysAlaProProAspAlaValArgAlaAlaAlaLeuProProGln280 285290ACTCCACCGCAGACCCGCAGGAGGCGGCGTGCCAAGATCACCGGCCGG1027ThrProProGlnThrArgArgArgArgArgAlaLysIleThrGlyArg295 300305GAGCGCAAGGCCATGAGGGTCCTGCCGGTGGTGGTCGGGGCCTTCCTG1075GluArgLysAlaMetArgValLeuProValValValGlyAlaPheLeu310315 320CTGTGCTGGACGCCCTTCTTCGTGGTGCACATCACGCAGGCGCTGTGT1123LeuCysTrpThrProPhePheValValHisIleThrGlnAlaLeuCys325330 335340CCTGCCTGCTCCGTGCCCCCGCGGCTGGTCAGCGCCGTCACCTGGCTG1171ProAlaCysSerValProProArgLeuValSerAlaValThrTrpLeu345 350355GGCTACGTCAACAGCGCCCTCACCCCCGTCATCTACACTGTCTTCAAC1219GlyTyrValAsnSerAlaLeuThrProValIleTyrThrValPheAsn360 365370GCCGAGTTCCGCAACGTCTTCCGCAAGGCCCTGCGTGCCTGCTGCTGAGCCGG1274AlaGluPheArgAsnValPheArgLysAlaLeuArgAlaCysCys375 380385ACCCCCGGACGCCCCCCGGCCTGATGGCCAGGCCTCAGGGACCAAGGAGATGGGGAGGGC1334GCTTTTGTACGTTAATTAAACAAATTCCTTCCCAAA1370(2) INFORMATION FOR SEQ ID NO:2:(i ) SEQUENCE CHARACTERISTICS:(A) LENGTH: 387 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:MetGlyAsnArgSerThrAlaAspAlaAspGlyLeuLeuAlaGlyArg151 015GlyArgAlaAlaGlyAlaSerAlaGlyAlaSerAlaGlyLeuAlaGly202530GlnGlyAlaAlaAlaLeuValGlyGlyValLeuLeuIl eGlyAlaVal354045LeuAlaGlyAsnSerLeuValCysValSerValAlaThrGluArgAla505560LeuGlnThr ProThrAsnSerPheIleValSerLeuAlaAlaAlaAsp65707580LeuLeuLeuAlaLeuLeuValLeuProLeuPheValTyrSerGluVal 859095GlnGlyGlyAlaTrpLeuLeuSerProArgLeuCysAspAlaLeuMet100105110AlaMetAspValMetLeuC ysThrAlaSerIlePheAsnLeuCysAla115120125IleSerValAspArgPheValAlaValAlaValProLeuArgTyrAsn130135 140ArgGlnGlyGlySerArgArgGlnLeuLeuLeuIleGlyAlaThrTrp145150155160LeuLeuSerAlaAlaValAlaAlaProValLeuCysGlyLe uAsnAsp165170175ValArgGlyArgAspProAlaValCysArgLeuGluAspArgAspTyr180185190 ValValTyrSerSerValCysSerPhePheLeuProCysProLeuMet195200205LeuLeuLeuTyrTrpAlaThrPheArgGlyLeuGlnArgTrpGluVal210 215220AlaArgArgAlaLysLeuHisGlyArgAlaProArgArgProSerGly225230235240ProGlyProProSerProThrP roProAlaProArgLeuProGlnAsp245250255ProCysGlyProAspCysAlaProProAlaProGlyLeuProProAsp26026 5270ProCysGlySerAsnCysAlaProProAspAlaValArgAlaAlaAla275280285LeuProProGlnThrProProGlnThrArgArgArgArgAr gAlaLys290295300IleThrGlyArgGluArgLysAlaMetArgValLeuProValValVal305310315320Gly AlaPheLeuLeuCysTrpThrProPhePheValValHisIleThr325330335GlnAlaLeuCysProAlaCysSerValProProArgLeuValSerAla 340345350ValThrTrpLeuGlyTyrValAsnSerAlaLeuThrProValIleTyr355360365ThrValPheAsnAlaGluPheA rgAsnValPheArgLysAlaLeuArg370375380AlaCysCys385(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1466 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single (D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(ix) FEATURE:(A) NAME/KEY: 5&#39;UTR(B) LOCATION: 1..103(ix) FEATURE:(A) NAME/KEY: 3&#39;UTR(B) LOCATION: 1364..1466(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 104..1363(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:CGGGGGCG GGACCAGGGTCCGGCCGGGGCGTGCCCCCGGGGAGGGACTCCCCGGCTTGCC60CCCCGGCGTTGTCCGCGGTGCTCAGCGCCCGCCCGGGCGCGCCATGGGGAACCGC115MetGlyA snArgAGCACCGCGGACGCGGACGGGCTGCTGGCTGGGCGCGGGCGGGCCGCG163SerThrAlaAspAlaAspGlyLeuLeuAlaGlyArgGlyArgAlaA la5101520GGGGCATCTGCGGGGGCATCTGCGGGGCTGGCTGGGCAGGGCGCGGCG211GlyAlaSerAlaGlyAlaSerAlaGlyLeuAlaGlyGlnG lyAlaAla253035GCGCTGGTGGGGGGCGTGCTGCTCATCGGCGCGGTGCTCGCGGGGAAC259AlaLeuValGlyGlyValLeuLeuIleGlyAlaValL euAlaGlyAsn404550TCGCTCGTGTGCGTGAGCGTGGCCACCGAGCGCGCCCTGCAGACGCCC307SerLeuValCysValSerValAlaThrGluArgAlaL euGlnThrPro556065ACCAACTCCTTCATCGTGAGCCTGGCGGCCGCCGACCTCCTCCTCGCT355ThrAsnSerPheIleValSerLeuAlaAlaAlaAspLeuL euLeuAla707580CTCCTGGTGCTGCCGCTCTTCGTCTACTCCGAGGTCCAGGGTGGCGCG403LeuLeuValLeuProLeuPheValTyrSerGluValGlnGlyGlyA la859095100TGGCTGCTGAGCCCCCGCCTGTGCGACGCCCTCATGGCCATGGACGTC451TrpLeuLeuSerProArgLeuCysAspAlaLeuMetAlaM etAspVal105110115ATGCTGTGCACCGCCTCCATCTTCAACCTGTGCGCCATCAGCGTGGAC499MetLeuCysThrAlaSerIlePheAsnLeuCysAlaI leSerValAsp120125130AGGTTCGTGGCCGTGGCCGTGCCGCTGCGCTACAACCGGCAGGGTGGG547ArgPheValAlaValAlaValProLeuArgTyrAsnA rgGlnGlyGly135140145AGCCGCCGGCAGCTGCTGCTCATCGGCGCCACGTGGCTGCTGTCCGCG595SerArgArgGlnLeuLeuLeuIleGlyAlaThrTrpLeuL euSerAla150155160GCGGTGGCGGCGCCCGTACTGTGCGGCCTCAACGACGTGCGCGGCCGC643AlaValAlaAlaProValLeuCysGlyLeuAsnAspValArgGlyA rg165170175180GACCCCGCCGTGTGCCGCCTGGAGGACCGCGACTACGTGGTCTACTCG691AspProAlaValCysArgLeuGluAspArgAspTyrValV alTyrSer185190195TCCGTGTGCTCCTTCTTCCTACCCTGCCCGCTCATGCTGCTGCTGTAC739SerValCysSerPhePheLeuProCysProLeuMetL euLeuLeuTyr200205210TGGGCCACGTTCCGCGGCCTGCAGCGCTGGGAGGTGGCACGTCGCGCC787TrpAlaThrPheArgGlyLeuGlnArgTrpGluValA laArgArgAla215220225AAGCTGCACGGCCGCGCGCCCCGCCGACCCAGCGGCCCTGGCCCGCCT835LysLeuHisGlyArgAlaProArgArgProSerGlyProG lyProPro230235240TCCCCCACGCCACCCGCGCCCCGCCTCCCCCAGGACCCCTGCGGCCCC883SerProThrProProAlaProArgLeuProGlnAspProCysGlyP ro245250255260GACTGTGCGCCCCCCGCGCCCGGCCTTCCCCGGGGTCCCTGCGGCCCC931AspCysAlaProProAlaProGlyLeuProArgGlyProC ysGlyPro265270275GACTGTGCGCCCGCCGCGCCCAGCCTCCCCCAGGACCCCTGCGGCCCC979AspCysAlaProAlaAlaProSerLeuProGlnAspP roCysGlyPro280285290GACTGTGCGCCCCCCGCGCCCGGCCTCCCCCCGGACCCCTGCGGCTCC1027AspCysAlaProProAlaProGlyLeuProProAspP roCysGlySer295300305AACTGTGCTCCCCCCGACGCCGTCAGAGCCGCCGCGCTCCCACCCCAG1075AsnCysAlaProProAspAlaValArgAlaAlaAlaLeuP roProGln310315320ACTCCACCGCAGACCCGCAGGAGGCGGCGTGCCAAGATCACCGGCCGG1123ThrProProGlnThrArgArgArgArgArgAlaLysIleThrGlyA rg325330335340GAGCGCAAGGCCATGAGGGTCCTGCCGGTGGTGGTCGGGGCCTTCCTG1171GluArgLysAlaMetArgValLeuProValValValGlyA laPheLeu345350355CTGTGCTGGACGCCCTTCTTCGTGGTGCACATCACGCAGGCGCTGTGT1219LeuCysTrpThrProPhePheValValHisIleThrG lnAlaLeuCys360365370CCTGCCTGCTCCGTGCCCCCGCGGCTGGTCAGCGCCGTCACCTGGCTG1267ProAlaCysSerValProProArgLeuValSerAlaV alThrTrpLeu375380385GGCTACGTCAACAGCGCCCTCACCCCCGTCATCTACACTGTCTTCAAC1315GlyTyrValAsnSerAlaLeuThrProValIleTyrThrV alPheAsn390395400GCCGAGTTCCGCAACGTCTTCCGCAAGGCCCTGCGTGCCTGCTGCTGAGCCGG1370AlaGluPheArgAsnValPheArgLysAlaLeuArgAlaCysCys 405410415420ACCCCCGGACGCCCCCCGGCCTGATGGCCAGGCCTCAGGGACCAAGGAGATGGGGAGGGC1430GCTTTTGTACGTTAATTAAACAAATTCCTTCCCAAA 1466(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 419 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:MetGlyAsnArgSerThrAlaAspAlaAspGlyLeuLeuAlaGlyArg151015GlyArgAlaAlaGlyAlaSerAlaGlyAlaSerAlaGlyLeuAlaGly202530GlnGlyAl aAlaAlaLeuValGlyGlyValLeuLeuIleGlyAlaVal354045LeuAlaGlyAsnSerLeuValCysValSerValAlaThrGluArgAla50 5560LeuGlnThrProThrAsnSerPheIleValSerLeuAlaAlaAlaAsp65707580LeuLeuLeuAlaLeuLeuValLeuProLeu PheValTyrSerGluVal859095GlnGlyGlyAlaTrpLeuLeuSerProArgLeuCysAspAlaLeuMet100105 110AlaMetAspValMetLeuCysThrAlaSerIlePheAsnLeuCysAla115120125IleSerValAspArgPheValAlaValAlaValProLeuArgTyrAsn130135140ArgGlnGlyGlySerArgArgGlnLeuLeuLeuIleGlyAlaThrTrp145150155160LeuLeuSerAl aAlaValAlaAlaProValLeuCysGlyLeuAsnAsp165170175ValArgGlyArgAspProAlaValCysArgLeuGluAspArgAspTyr180 185190ValValTyrSerSerValCysSerPhePheLeuProCysProLeuMet195200205LeuLeuLeuTyrTrpAlaThrPheArgGly LeuGlnArgTrpGluVal210215220AlaArgArgAlaLysLeuHisGlyArgAlaProArgArgProSerGly225230235 240ProGlyProProSerProThrProProAlaProArgLeuProGlnAsp245250255ProCysGlyProAspCysAlaProProAlaProGlyLeuProArg Gly260265270ProCysGlyProAspCysAlaProAlaAlaProSerLeuProGlnAsp275280285ProCysGlyPr oAspCysAlaProProAlaProGlyLeuProProAsp290295300ProCysGlySerAsnCysAlaProProAspAlaValArgAlaAlaAla305310 315320LeuProProGlnThrProProGlnThrArgArgArgArgArgAlaLys325330335IleThrGlyArgGluArgLysAlaMet ArgValLeuProValValVal340345350GlyAlaPheLeuLeuCysTrpThrProPhePheValValHisIleThr355360 365GlnAlaLeuCysProAlaCysSerValProProArgLeuValSerAla370375380ValThrTrpLeuGlyTyrValAsnSerAlaLeuThrProValIleTyr385 390395400ThrValPheAsnAlaGluPheArgAsnValPheArgLysAlaLeuArg405410415AlaCysCy s(2) INFORMATION FOR SEQ ID NO:5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1610 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(ix) FEATURE:(A) NAME/KEY: 5&#39;UTR(B) LOCATION: 1..103(ix) FEATURE:(A) NAME/KEY: 3&#39;UTR(B) LOCATION: 1508..1610(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 104..1507(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:CGGGGGCGGGACCAGGGTCCGGCCGGGGCGTGCCCCCGGGGAGGGACTCCCCGGCTTGCC60CCCCGGCGTTGTCCGCGGTGCTCAGCGCCCGCC CGGGCGCGCCATGGGGAACCGC115MetGlyAsnArg1AGCACCGCGGACGCGGACGGGCTGCTGGCT GGGCGCGGGCGGGCCGCG163SerThrAlaAspAlaAspGlyLeuLeuAlaGlyArgGlyArgAlaAla5101520GGGGCATCTGCGGGGGCATCTGCG GGGCTGGCTGGGCAGGGCGCGGCG211GlyAlaSerAlaGlyAlaSerAlaGlyLeuAlaGlyGlnGlyAlaAla253035GCGCTGGTGGGGGGCGTGCTG CTCATCGGCGCGGTGCTCGCGGGGAAC259AlaLeuValGlyGlyValLeuLeuIleGlyAlaValLeuAlaGlyAsn404550TCGCTCGTGTGCGTGAGCGTG GCCACCGAGCGCGCCCTGCAGACGCCC307SerLeuValCysValSerValAlaThrGluArgAlaLeuGlnThrPro556065ACCAACTCCTTCATCGTGAGCCTG GCGGCCGCCGACCTCCTCCTCGCT355ThrAsnSerPheIleValSerLeuAlaAlaAlaAspLeuLeuLeuAla707580CTCCTGGTGCTGCCGCTCTTCGTCTACTCC GAGGTCCAGGGTGGCGCG403LeuLeuValLeuProLeuPheValTyrSerGluValGlnGlyGlyAla859095100TGGCTGCTGAGCCCCCGCCTGTGC GACGCCCTCATGGCCATGGACGTC451TrpLeuLeuSerProArgLeuCysAspAlaLeuMetAlaMetAspVal105110115ATGCTGTGCACCGCCTCCATC TTCAACCTGTGCGCCATCAGCGTGGAC499MetLeuCysThrAlaSerIlePheAsnLeuCysAlaIleSerValAsp120125130AGGTTCGTGGCCGTGGCCGTG CCGCTGCGCTACAACCGGCAGGGTGGG547ArgPheValAlaValAlaValProLeuArgTyrAsnArgGlnGlyGly135140145AGCCGCCGGCAGCTGCTGCTCATC GGCGCCACGTGGCTGCTGTCCGCG595SerArgArgGlnLeuLeuLeuIleGlyAlaThrTrpLeuLeuSerAla150155160GCGGTGGCGGCGCCCGTACTGTGCGGCCTC AACGACGTGCGCGGCCGC643AlaValAlaAlaProValLeuCysGlyLeuAsnAspValArgGlyArg165170175180GACCCCGCCGTGTGCCGCCTGGAG GACCGCGACTACGTGGTCTACTCG691AspProAlaValCysArgLeuGluAspArgAspTyrValValTyrSer185190195TCCGTGTGCTCCTTCTTCCTA CCCTGCCCGCTCATGCTGCTGCTGTAC739SerValCysSerPhePheLeuProCysProLeuMetLeuLeuLeuTyr200205210TGGGCCACGTTCCGCGGCCTG CAGCGCTGGGAGGTGGCACGTCGCGCC787TrpAlaThrPheArgGlyLeuGlnArgTrpGluValAlaArgArgAla215220225AAGCTGCACGGCCGCGCGCCCCGC CGACCCAGCGGCCCTGGCCCGCCT835LysLeuHisGlyArgAlaProArgArgProSerGlyProGlyProPro230235240TCCCCCACGCCACCCGCGCCCCGCCTCCCC CAGGACCCCTGCGGCCCC883SerProThrProProAlaProArgLeuProGlnAspProCysGlyPro245250255260GACTGTGCGCCCCCCGCGCCCGGC CTTCCCCGGGGTCCCTGCGGCCCC931AspCysAlaProProAlaProGlyLeuProArgGlyProCysGlyPro265270275GACTGTGCGCCCGCCGCGCCC GGCCTCCCCCCGGACCCCTGCGGCCCC979AspCysAlaProAlaAlaProGlyLeuProProAspProCysGlyPro280285290GACTGTGCGCCCCCCGCGCCC GGCCTCCCCCAGGACCCCTGCGGCCCC1027AspCysAlaProProAlaProGlyLeuProGlnAspProCysGlyPro295300305GACTGTGCGCCCCCCGCGCCCGGC CTTCCCCGGGGTCCCTGCGGCCCC1075AspCysAlaProProAlaProGlyLeuProArgGlyProCysGlyPro310315320GACTGTGCGCCCCCCGCGCCCGGCCTCCCC CAGGACCCCTGCGGCCCC1123AspCysAlaProProAlaProGlyLeuProGlnAspProCysGlyPro325330335340GACTGTGCGCCCCCCGCGCCCGGC CTCCCCCCGGACCCCTGCGGCTCC1171AspCysAlaProProAlaProGlyLeuProProAspProCysGlySer345350355AACTGTGCTCCCCCCGACGCC GTCAGAGCCGCCGCGCTCCCACCCCAG1219AsnCysAlaProProAspAlaValArgAlaAlaAlaLeuProProGln360365370ACTCCACCGCAGACCCGCAGG AGGCGGCGTGCCAAGATCACCGGCCGG1267ThrProProGlnThrArgArgArgArgArgAlaLysIleThrGlyArg375380385GAGCGCAAGGCCATGAGGGTCCTG CCGGTGGTGGTCGGGGCCTTCCTG1315GluArgLysAlaMetArgValLeuProValValValGlyAlaPheLeu390395400CTGTGCTGGACGCCCTTCTTCGTGGTGCAC ATCACGCAGGCGCTGTGT1363LeuCysTrpThrProPhePheValValHisIleThrGlnAlaLeuCys405410415420CCTGCCTGCTCCGTGCCCCCGCGG CTGGTCAGCGCCGTCACCTGGCTG1411ProAlaCysSerValProProArgLeuValSerAlaValThrTrpLeu425430435GGCTACGTCAACAGCGCCCTC ACCCCCGTCATCTACACTGTCTTCAAC1459GlyTyrValAsnSerAlaLeuThrProValIleTyrThrValPheAsn440445450GCCGAGTTCCGCAACGTCTTC CGCAAGGCCCTGCGTGCCTGCTGCTGAGCCGG1514AlaGluPheArgAsnValPheArgLysAlaLeuArgAlaCysCys455460465ACCCCCGGACGCCCCCCGGCCTGATGGCCAGGC CTCAGGGACCAAGGAGATGGGGAGGGC1574GCTTTTGTACGTTAATTAAACAAATTCCTTCCCAAA1610(2) INFORMATION FOR SEQ ID NO:6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 467 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:MetGlyAsnArgSerThrAlaAspAlaAspGlyLeuLeuAlaGlyArg151015GlyArgAlaAlaGlyAlaSerAlaGlyAla SerAlaGlyLeuAlaGly202530GlnGlyAlaAlaAlaLeuValGlyGlyValLeuLeuIleGlyAlaVal3540 45LeuAlaGlyAsnSerLeuValCysValSerValAlaThrGluArgAla505560LeuGlnThrProThrAsnSerPheIleValSerLeuAlaAlaAlaAsp65 707580LeuLeuLeuAlaLeuLeuValLeuProLeuPheValTyrSerGluVal859095GlnGlyGlyAl aTrpLeuLeuSerProArgLeuCysAspAlaLeuMet100105110AlaMetAspValMetLeuCysThrAlaSerIlePheAsnLeuCysAla115 120125IleSerValAspArgPheValAlaValAlaValProLeuArgTyrAsn130135140ArgGlnGlyGlySerArgArgGlnLeuLeuLeuIleGly AlaThrTrp145150155160LeuLeuSerAlaAlaValAlaAlaProValLeuCysGlyLeuAsnAsp165170 175ValArgGlyArgAspProAlaValCysArgLeuGluAspArgAspTyr180185190ValValTyrSerSerValCysSerPhePheLeuProCysProLeuMet195200205LeuLeuLeuTyrTrpAlaThrPheArgGlyLeuGlnArgTrpGluVal210215220AlaArgArgAlaLysLeuHi sGlyArgAlaProArgArgProSerGly225230235240ProGlyProProSerProThrProProAlaProArgLeuProGlnAsp245 250255ProCysGlyProAspCysAlaProProAlaProGlyLeuProArgGly260265270ProCysGlyProAspCysAlaProAlaAla ProGlyLeuProProAsp275280285ProCysGlyProAspCysAlaProProAlaProGlyLeuProGlnAsp290295300P roCysGlyProAspCysAlaProProAlaProGlyLeuProArgGly305310315320ProCysGlyProAspCysAlaProProAlaProGlyLeuProGlnAsp 325330335ProCysGlyProAspCysAlaProProAlaProGlyLeuProProAsp340345350ProCysGlySe rAsnCysAlaProProAspAlaValArgAlaAlaAla355360365LeuProProGlnThrProProGlnThrArgArgArgArgArgAlaLys370375 380IleThrGlyArgGluArgLysAlaMetArgValLeuProValValVal385390395400GlyAlaPheLeuLeuCysTrpThrProPhePhe ValValHisIleThr405410415GlnAlaLeuCysProAlaCysSerValProProArgLeuValSerAla420425 430ValThrTrpLeuGlyTyrValAsnSerAlaLeuThrProValIleTyr435440445ThrValPheAsnAlaGluPheArgAsnValPheArgLysAlaLeuArg 450455460AlaCysCys465